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Background: Recent studies worldwide have reported increasing numbers of adults diagnosed with Bordetella
pertussis despite receiving childhood vaccinations. This study describes a pertussis outbreak at a university medical
faculty campus and examines the effectiveness of diphtheria, tetanus, and pertussis (DTaP) vaccination completed
during infancy in Japan.
Methods: After the outbreak, self-administered questionnaires and serum samples were collected from students on
campus to determine the incidence of pertussis and underlying diseases. Pertussis was diagnosed on the basis of
clinical criteria and serum anti-pertussis toxin antibody levels. Using data collected from 248 first and second grade
students who had submitted copies of their vaccination records, we evaluated the effectiveness of DTaP vaccination
in infancy against adult pertussis.
Results: Questionnaire responses were obtained from 636 students (of 671 registered students; 95% response rate).
Of 245 students who reported a continuous cough during the outbreak period, 84 (attack rate: 13.2%) were
considered “probable” pertussis cases that met clinical criteria. The outbreak occurred mainly in first and second
grade students in the Faculty of Medicine. Of 248 students who provided vaccination records, 225 had received 4
DTaP doses (coverage: 90.7%); the relative risk of the complete vaccination series compared to those with fewer
than 4 doses or no doses for probable cases was 0.48 (95% confidence interval: 0.24-0.97).
Conclusions: Waning protection was suspected due to over time. Booster vaccination for teenagers and
development of highly efficacious pertussis vaccines are needed.
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Although global vaccination coverage for diphtheria, tet-
anus, and pertussis (DTaP) remains high, recent reports
of increasing pertussis cases among adolescents and
adults are of concern because this population can be a
source of infant infection [1]. Suggested causes for this
increase include increased clinical awareness of per-
tussis, improved diagnostics using polymerase chain
reaction (PCR), identification of mutations in the strain
of Bordetella pertussis associated with epidemics, and* Correspondence: harameg@cc.saga-u.ac.jp
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unless otherwise stated.decreasing antibody titers after vaccination [2-6]. Western
countries have initiated tetanus, reduced-antigen-content
diphtheria, and acellular pertussis (Tdap) vaccine booster
programs for adolescents, adults, and other high-risk
groups [1,7,8].
The number of adult pertussis cases has been increas-
ing in Japan, with outbreaks in high schools and univer-
sities as well as workplaces successively reported in 2002
[9-13]. In response to these reports, studies have exa-
mined outbreak characteristics, genetic characteristics
of B. pertussis, and alternative diagnostic methods.
However, to our knowledge, no study has evaluated the
effectiveness of the current DTaP vaccine. Japan has
a different schedule to western countries for babyis is an Open Access article distributed under the terms of the Creative
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tussis vaccination is a triple DTaP vaccine (after 2012,
DTaP-IPV), beginning at 3 months of age. To establish
initial immunity, 3 times for 3 to 8 weeks apart are
needed. A booster dose is given at 6 months to 12 months
after the initial immunity. Thus, DTaP vaccine is usually
completed by 18 months of age. The recommended num-
ber of doses is smaller than that in Western countries. In
addition, Tdap booster vaccines are not administered after
early adolescence in Japan. To determine the necessity for
booster vaccination in early adolescence, it is important to
evaluate the effectiveness of the current vaccine program
in preventing pertussis after early adolescence. However,
there have been a limited number of epidemiological eval-
uations on vaccine program effectiveness against pertussis
in Japan, and these studies have focused primarily on chil-
dren [14,15]. To our knowledge, no studies have examined
the effectiveness of the vaccine against pertussis after early
adolescence.
In April 2010, a pertussis outbreak was confirmed
among students at the medical faculty campus of Saga
University. After the outbreak ended, a retrospective
cohort study was performed. This study describes the
outbreak and examines the association between infant
DTaP vaccination and incidence of pertussis.
Methods
Study populations
More than 20 students visited the health administration
center at the Saga University Faculty of Medicine in
April 2010 complaining of coughs that had lasted at
least 2 weeks. Three of these students had throat swabs
positive for B. pertussis by loop-mediated isothermal
amplification [16]. Thus, this outbreak of cough symp-
toms was considered to be due to pertussis. The health
administration center discouraged club activities, meet-
ings, and ball game tournaments; promoted use of face-
masks; terminated practical training for students with
coughs; actively encouraged medical examinations at
medical institutions; and notified students and faculty
members of the outbreak by e-mail. By early July, no
new cough cases were reported to the health administra-
tion center.
Just after the end of the outbreak in early July, a total
of 671 students (411 and 260 from the departments of
medicine and nursing, respectively) from the first
through fourth grades on the faculty of medicine cam-
pus were provided an oral explanation of the purpose,
content, and conditions of cooperation of the study, and
asked to provide written informed consent forms with
agreement to participate. Among them, 636 students
(collection rate: 95%) completed a questionnaire about
relevant demographic variables and clinical symptoms
of cough, including duration, presence of coughingparoxysms, whooping and vomiting after cough, medical
institution visits, past history of disease, and DTaP vac-
cination status. They were also asked to provide serum
specimens. Serum samples were obtained from 516
(77.1%) of these students; anti-pertussis toxin (PT) anti-
body levels were tested by enzyme immunoassay at an
outside laboratory (SRL, Inc., Tokyo).
Of these, 248 first and second grade students had sub-
mitted copies of their vaccination records, including
infant DTaP vaccine administration histories, from their
maternity record books to the health administration cen-
ter upon entering the school. In Japan, vaccination his-
tories are recorded in maternity record books maintained
by individuals.
This study design was approved by the ethical review
board of the Saga Medical School Faculty of Medicine,
Saga University (approval number 22–25, 2010).
Case definitions
Cases were categorized on the basis of 2 clinical defini-
tions of pertussis, using clinical criteria established by
the Centers for Disease Control and Prevention and the
Council of State and Territorial Epidemiologists 2014
case definitions [17]. “Probable cases” had cough illness
lasting ≥2 weeks with at least 1 of the following signs
or symptoms: paroxysms of coughing, or inspiratory
“whoop”, or posttussive vomiting. “Suspected cases” met
at least 1 of the 4 clinical symptoms or signs. In addition
to these clinical definitions, the serological diagnosis of
pertussis required serum anti-PT antibody levels after
the outbreak to be higher than 100 EU/mL.
Vaccine effectiveness
The 248 students whose vaccination records could be
confirmed by their maternity record books were clas-
sified into 2 groups: those who had completed the full
4-dose vaccination as recommended by the Japanese
government, those who had received less than 4 vaccine
doses or no doses. The attack rate (AR) of pertussis and
the relative risk (RR) after 4 doses compared with less
than 4 doses or no doses were calculated. The effective-
ness of the vaccine was calculated using the equation:
1 − ARvaccinated=ARunvaccinated½ ð Þ  100 %ð Þ
¼ 1 – RRð Þ  100 %ð Þ
Statistical analysis
We used SAS 9.3 for Windows (SAS Institute, Cary, NC,
USA) for statistical comparisons between each variable
using chi-square and Fisher’s exact tests. RRs after 4
doses compared with less than 4 doses or no doses and
corresponding 95% confidence intervals (CIs) were ob-
tained using the PROC FREQ procedure in the software
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obtained using the Mantel–Haenszel method.
Results
Description of outbreak
The population characteristics and cough statuses of 636
subjects who participated in the survey just after the
outbreak were examined according to clinical diagnosis
(Table 1). Among 245 students (38.5%) who presented
with a cough during the outbreak period, the most com-
mon cough duration was 2 weeks or more, followed by
duration of 1–2 weeks. The most common characteristic
was paroxysmal cough, followed by posttussive vomiting.













Continuous cough Yes 2
Less than 1 week 3
1 week or more and less than
2 weeks
1
2 weeks or more 1
Characters of continuous cough
(multiple answers)
Proxysms of coughing 2
Inspiratory whooping 2
Posttussive vomiting 7
Medical institution Visited 1









Clinical criteria: (1) cough illness lasting ≧ 2 weeks; (2) paroxysms of coughing; (3) in
Suspected case: patient with at least 1 clinical criterion.
Probable case: patient with cough illness lasting ≥ 2 weeks with at least 1 other clin
*Chi-square test.161 students were classified into the probable case
(mean age 20.4, range: 18–34 years) and suspected case
(mean age 20.0, range: 18–30 years) groups, respectively.
The number of cases was greatest in first grade students
in the Department of Medicine. Of 245 students with
continuous cough, 121 visited a medical institution; of
these, 56 were diagnosed with pertussis by physicians.
Patients with probable cases were more likely to seek
treatment at a medical institution and be diagnosed with
pertussis than those with suspected cases. Of the stu-
dents diagnosed with pertussis, 21 had visited the in-
fection control department at the university hospital.
Pertussis DNA was detected in throat swabs obtained










(%) n (%) n (%) n (%)
89 61.2 224 57.3 107 66.5 58 69.0 0.037
47 38.8 167 42.7 54 33.5 26 31.0
64 25.8 85 21.7 54 33.5 25 29.8 0.079
58 24.8 96 24.6 59 36.6 23 27.4
56 24.5 105 26.9 35 21.7 16 19.0
58 24.8 105 26.9 33 20.5 20 23.8
43 38.2 152 38.9 56 34.8 35 41.7 0.517
92 61.6 238 60.9 105 65.2 49 58.3
0.2 1 0.3 0 0.0 0 0.0
45 38.5 0 161 100.0 84 100.0
8 6.0 - 38 23.6 0 0.0 <0.001
02 16.0 - 102 63.4 0 0.0
05 16.5 - 21 13.0 84 100.0
33 36.6 - 152 94.4 81 96.4 0.48
2 3.5 - 12 7.5 10 11.9 0.247
0 11.0 - 31 19.3 39 46.4 <0.0001
21 19.0 - 67 41.6 54 64.3 0.0008
6 8.8 - 30 18.6 26 31.0 0.0323
1.1 5 1.3 2 1.2 0 0.0 <0.001
9 3.0 9 2.3 4 2.5 6 7.1
9 3.0 8 2.0 3 1.9 8 9.5
0 1.6 5 1.3 5 3.1 0 0.0
7 7.4 20 5.1 15 9.3 12 14.3
34 84.0 344 88.0 132 82.0 58 69.0
spiratory “whoop”; (4) post-tussive vomiting.
ical criterion.
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of pertussis. Most students (534 of 636) could not re-
member their vaccination status.
The epidemic curve based on the date of cough onset
is shown in Figure 1. The number of individuals with
cough symptoms increased rapidly from early April and
decreased after peaking from April 19 to 25. No prophy-
laxis antibiotics were administered during this time.
Figure 2 shows the distribution of anti-PT antibody
titers in 516 students from whom serum was collected
after the outbreak, according to grade. Among them 24
subjects’ anti-PT antibody levels were greater than 100
(EU/mL), and the percentage of them was highest in first
grade students.
Evaluation of vaccine effectiveness
Among entire population, 248 first and second grade
students whose infant vaccination records could be con-
firmed by maternity record books were examined ac-
cording to clinical diagnosis (Table 2). Probable cases
were more common in the Department of Medicine. No
significant associations were found between grade, sex,
and underlying disease and incidence of pertussis. The
percentage of students diagnosed with pertussis who had
also received the full recommended DTaP vaccination
course in infancy was notably low (12.5%). The AR of
probable cases per vaccination status was 33% in unvac-
cinated students and 13.8% in students who had received
all 4 doses, indicating that ARs were lowest in students
who had received the recommended number of vaccine
doses.
There were no statistically significant differences in
the department, grade, sex, or underlying diseases com-
pared to the completeness of the infant vaccination
series. A significantly higher proportion of individuals
who did not receive 4 doses of DTaP reported coughingFigure 1 Epidemic curve based on date of cough onset. Dark gray andparoxysms. While the clinical characteristics of cough
varied, the proportion of students with anti-PT antibody
levels greater than 100 EU/mL after the outbreak were
similar between those who did and those who did not
receive a full vaccine dose (see Additional file 1: Table S1).
We examined the RR of the DTaP vaccine for those who
had received the government-recommended number of
vaccinations in infancy (Table 3). When outcome was
defined as probable cases based on the clinical criteria,
the RR for students with 4 doses compared to those
with fewer than 4 doses or no doses was 0.48 (95%
CI: 0.24–0.97); after adjusting for the impact of depart-
ment the effectiveness was estimated to be 52% (95% CI:
3–76). Similarly, when outcome was defined as meeting at
least 1 of the 4 clinical criteria in both probable and
suspected cases, the adjusted RR was 0.70 (95% CI:
0.51–0.98). When outcomes were defined as serological
diagnosis of pertussis after the outbreak (anti-PT antibody
levels greater than 100 EU/mL) or diagnosed at medical
institutions, the RRs were 0.64 (95% CI: 0.16–2.52) and
0.74 (95% CI: 0.21–2.61), respectively; no statistically
significant protective effect of complete vaccination were
detected using these outcome definitions.
Discussion
The outbreak in this study occurred mainly in first and
second grade students on the university campus, with
peak incidence in April. Welcoming parties for new
pupils or invitations to club activities before and after
entrance ceremonies likely contributed to the spread of in-
fection. The outbreak ended without administration of
preventive antibiotics. Measures such as self-restraint of
club activities, meetings, and ball game tournaments, ter-
mination of practical trainings, and active intervention by
the health administration center to encourage exami-
nation at medical institutions appeared to effectively limitlight gray bars indicate suspected and probable cases, respectively.
Figure 2 Distribution of serum pertussis toxin antibodies in 516 students after the outbreak, according to grade. Black, gray, black with
dots, and gray with dots bars indicate first, second, third, and fourth grades, respectively.
Table 2 Comparison of underlying disease and DTaP vaccination according to clinical diagnosis in 248 students with
confirmed vaccination records







(n = 248) n (%) n (%) n (%)
Department Medicine 156 76 57.1 51 66.2 29 76.3 0.0075
Nursing 92 57 42.9 26 33.8 9 23.7
Grade 1 133 64 48.1 47 61.0 22 57.9 0.1652
2 115 69 51.9 30 39.0 16 42.1
Sex Male 102 53 39.8 30 39.0 19 50.0 0.4784
Female 146 80 60.2 47 61.0 19 50.0
History Allergic rhinitis 59 35 26.3 18 23.4 6 15.8 0.4032
Anemia 30 15 11.3 9 11.7 6 15.8 0.7474
Food Allergy 12 7 5.3 3 3.9 2 5.3 0.8979
Heart disease 2 2 1.5 0 0.0 0 0.0 0.4182
Liver disease 1 1 0.8 0 0.0 0 0.0 0.6479
Renal disease 4 4 3.0 0 0.0 0 0.0 0.1724
Diabetes 1 1 0.8 0 0.0 0 0.0 0.6479
None 90 48 36.1 32 41.6 10 26.3 0.2778
Vaccination record for DTaP vaccine
No 3 1 0.8 1 1.3 1 2.6 0.0742
1 shot 4 2 1.5 2 2.6 0 0.0
2 doses 2 0 0.0 0 0.0 2 5.3
3 doses 14 5 3.8 5 6.5 4 10.5
4 doses 225 125 94.0 69 89.6 31 81.6
DTaP: diphtheria, tetanus, and pertussis.
*Chi-square test or Fisher’s exact test.
Hara et al. BMC Infectious Diseases  (2015) 15:45 Page 5 of 8
Table 3 Relative risks of history of DTaP vaccination for pertussis according to case definition
Definition of pertussis Number Case Attack rate (%) Relative risk (95% CI) Relative riska (95% CI)
Probable cases
Less than 4 doses or no doses 23 7 30.4 1 1
4 doses 225 31 13.8 0.45 (0.23-0.91) 0.48 (0.24-0.97)
Probable + Suspected cases
Less than 4 doses or no doses 23 15 65.2 1 1
4 doses 225 100 44.4 0.68 (0.49-0.95) 0.70 (0.51-0.98)
Anti- PT antibody titers after outbreak≥ 100EU/mL
Less than 4 doses or no doses 23 2 8.7 1 1
4 doses 225 13 5.8 0.64 (0.16-2.76) 0.64 (0.16-252)
Diagnosed as pertusis at medical institutions
Less than 4 doses or no doses 23 2 8.7 1 1
4 doses 225 17 7.6 0.87 (0.21-3.53) 0.74 (0.21-2.61)
DTaP: diptheria, tetanus, and pertussis; CI: confidence interval; PT: pertussis toxin.
Clinical criteria: (1) cough illness lasting ≧ 2 weeks; (2) paroxysms of coughing; (3) inspiratory “whoop”; (4) post-tussive vomiting.
Probable case: a patient who met cough illness lasting ≧ 2 weeks with at least 1 item in the other clinical criteria.
Suspected case: a patient who met at least 1 item in the above 4 clinical criteria.
aAdjusted by department using the Mantel-Haenszel method.
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sity holidays owing to consecutive holidays in May might
also have reduced the spread of infection.
The vaccine effectiveness was 52% for probable cases
meeting the clinical criteria for pertussis when students
with fewer than 4 or no shots was defined as the refe-
rence. It is difficult to directly compare these results
with other studies because booster vaccination recom-
mendations vary by country [1,7,8,18], studies use dif-
ferent case definitions [1,18,19], vaccine effectiveness
decreases with age-associated decreases in vaccine-
induced antibodies [5,20,21], and study subject charac-
teristics may also differ considerably between studies.
We report a vaccine effectiveness lower than the 96% ef-
fectiveness reported by case–control studies of children
in Japan with 3 or more vaccine doses compared to un-
vaccinated children [15], and about 80% reported by a
meta-analysis study of children who received 4 vaccine
doses [18]. Considering that the mean age in our study
population was 20.4 years, the length of time since the
last vaccination may contribute the lower vaccine ef-
fectiveness. This observation suggests that replacing the
conventional diphtheria and tetanus toxin vaccine ad-
ministered in adolescence to DTaP might be necessary
in Japan. In addition, complete vaccination in infancy is
essential, since incomplete vaccination did not show
protective effects against pertussis in this study.
In other countries, the DTaP vaccine is administered
in early childhood, and a Tdap booster vaccination is
administered after early adolescence. Therefore, there
are limited reports on the effectiveness of the DTaP vac-
cine in adolescents and adults. In a case–control studyperformed during an outbreak at a military school in
France, the vaccine effectiveness rates among bio-
logically confirmed cases where 5 and 4 DTaP vaccina-
tions were administered was 32% and 22%, respectively
[20]. This study also found that effectiveness decreased
as the period from the last vaccination increased. On the
other hand, 2 case–control studies in adolescents and
adults after Tdap booster vaccination reported an effec-
tiveness around 60%; these studies defined patients diag-
nosed with pertussis by PCR as cases and patients with
pertussis-like symptoms but negative by PCR as controls
[22,23]. In our study, the effectiveness of the DTaP vac-
cine was higher than that in a previous report from a US
military school and slightly lower than that of Tdap ef-
fectiveness. However, because the vaccination series is
completed by 2 years of age in Japan, 16 years or more
had passed since the last vaccination. We also defined
cases based on clinical criteria. Other reasons for these
disparate results may be due to the effects of boosters
administered during a pertussis outbreak in Japan in
2008 and 2009 [9-13]. Other reasons may include a
higher rate of completed vaccine courses: in our study
population, the vaccination coverage, or the percentage
of the study population that had received 4 vaccine
doses, was 94%. Differences in vaccine components
[24,25] and vaccination methods (subcutaneous injection
in Japan vs. intramuscular injection in the US) may also
have contributed to differences in reported results.
Generally, the more precisely defined the outcome, the
higher the diagnosis sensitivity [19], and detected effec-
tiveness. In our study, the vaccine effectiveness against
probable cases was higher than against suspected cases.
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detected by serologically or medically diagnosed cases.
In our study, patients with serum anti-PT antibody titers
greater than 100 EU/mL at the end of July were con-
sidered positive for pertussis, although we could not per-
form examinations with paired sera to compare levels
during the acute phase to the recovery phase of pertus-
sis. Anti-PT antibodies have been reported to decrease
particularly rapidly [26], so a patient with pertussis
might not show as positive if antibody levels had fallen
below this threshold. If many subjects with pertussis
were not detected by serological testing, misclassification
might occur. Medically diagnosed cases might be con-
founded by health-related behavior. Not all probable
cases visited medical institutions; thus, outcomes were
likely biased.
This study had several limitations. First, pertussis was
diagnosed only on the basis of clinical criteria. The clinical
definition of probable case includes a continuous cough
for 14 days or more. In this study, promotion of active in-
terventions and medical examinations at medical institu-
tions occurred during the early phase of the outbreak for
the purpose of infection control; as a result, the average
cough duration decreased, leading to potential misclassifi-
cation. Second, we could confirm vaccination records for
only half of the study participants. Although misclassifica-
tion of the vaccination category could be avoided by in-
cluding only those participants whose maternity record
books could confirm vaccination status, the sample size
would be quite small. However, since the outbreak of per-
tussis occurred mainly in first and second grade students
in our study, we believe that statistically significant diffe-
rences in vaccine efficacy could be detected. Third, the
past history of pertussis in the study participants is
unknown. Since outbreaks of pertussis in high school stu-
dents have also been recently reported in Japan [12], some
students may have been infected with pertussis before en-
tering the university. It is generally believed that a history
of pertussis is protective against future pertussis owing to
antibodies acquired by natural infection. Inclusion of sub-
jects with a history of pertussis in the group that had not
received 4 vaccinations in infancy could lead to underesti-
mated vaccine effectiveness. Finally, hygiene behaviors
might confound the association between the vaccination
record and onset. For example, if those who did not re-
ceive recommended infant vaccinations were also not
taught appropriate hygiene behaviors, they might not take
prophylactic actions against infection, such as washing
hands, wearing facemasks, and avoiding crowds during
the pertussis season. However, if these differences exist,
the effects are minimal, because vaccine effectiveness was
not detected when we examined the association between
measles vaccination with pertussis in the subjects of this
study (Additional file 2: Table S2).Conclusions
An outbreak of pertussis was observed in a population
in which the majority of individuals had completed the
DTaP vaccine course as infants. The AR was higher in
students who did not complete the full infant DTaP vac-
cine course. The vaccine effectiveness was an estimated
52%, lower than that described in previous reports of
children, mostly likely because of decreasing antibody
levels in the long period of time since their last DTaP
dose. These results suggest the necessity for booster vac-
cination for teenagers and development of highly effica-
cious pertussis vaccines.
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